Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Efficacia del sistema di stimolazione modulare EMPOWER™ e dell'ICD sottocutaneo EMBLEM™ per comunicare la stimolazione antitachicardica (MODULAR ATP)

9 novembre 2026 aggiornato da: Boston Scientific Corporation

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.

Panoramica dello studio

Stato

Attivo, non reclutante

Intervento / Trattamento

Descrizione dettagliata

The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

297

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Linz, Austria
        • Kepler Universitaetsklinikum
      • Québec, Canada
        • Institut Universitaire de Cardilogie et Pnuemologie de Quebec (IUCPQ)
    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Institut de Cardiologie de Quebec (Montreal Heart)
      • Prague, Cechia
        • Na Homolce Hospital
      • Grenoble, Francia
        • CHU Grenoble - Hospital Michallon
      • Lille, Francia, 59000
        • CHRU de Lille
      • Nantes, Francia
        • CHU de Nantes-Hopital Laennec
      • Paris, Francia
        • Hospital European Georges-Pompidou
      • Brescia, Italia
        • Spedali Civil di Brescia
      • Cotignola, Italia
        • Maria Cecilia Hospital SPA
      • Naples, Italia, 80131
        • AZ Osp Monaldi
      • Pisa, Italia, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Amsterdam, Olanda
        • Amsterdam University Medical Center
      • Nieuwegein, Olanda
        • St. Antonius Ziekenhuis
      • Rotterdam, Olanda, 3015 CE
        • Erasmus MC University Medical Center
      • Leeds, Regno Unito, LS1 EX
        • The General Infirmary
      • Liverpool, Regno Unito, L14 3PE
        • Liverpool Heart and Chest Hospital
      • Manchester, Regno Unito, M13 9WL
        • Manchester Heart Center
      • Southampton, Regno Unito
        • Southampton University Hospital
      • Barcelona, Spagna, 08036
        • Hospital Clinic of Barcelona
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006
        • Banner University Medical Center Phoenix
      • Scottsdale, Arizona, Stati Uniti, 84258
        • Scottsdale Healthcare - Shea
    • Arkansas
      • Jonesboro, Arkansas, Stati Uniti, 72401
        • Arrhythmia Research Group
    • Florida
      • Orlando, Florida, Stati Uniti, 32803
        • AdventHealth Orlando
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30308
        • Emory University Hospital
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40503
        • Baptist Health Lexington
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Mayo Clinic
    • New Jersey
      • Camden, New Jersey, Stati Uniti, 08103
        • Cooper Hospital - University Medical Center
    • New York
      • Manhasset, New York, Stati Uniti, 11030
        • Northwell University Hospital
      • New York, New York, Stati Uniti, 10029
        • Mount Sinai Medical Center
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44195
        • Cleveland Clinic
      • Columbus, Ohio, Stati Uniti, 43210
        • Ohio State University Medical Center
      • Columbus, Ohio, Stati Uniti, 43214
        • Ohio Health Research Institute
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Penn State Health Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Hospital of the University of Pennsylvania
    • Tennessee
      • Chattanooga, Tennessee, Stati Uniti, 37403
        • Erlanger Medical Center
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23507
        • Sentara Norfolk General
    • Washington
      • Seattle, Washington, Stati Uniti, 98195
        • University of Washington Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has an existing TV-ICD[iii] or S-ICD[iv]

  • Patient who is deemed to be at risk for MVT based on at least ONE of the following:

    • History of Non-Sustained MVT with LVEF ≤ 50%
    • History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant cardiac scar*
    • History of syncope deemed to be arrhythmic in origin
    • History of ischemic cardiomyopathy with LVEF ≤35%
    • History of non-ischemic cardiomyopathy with LVEF ≤35% and significant scar*
  • Patient who is willing and capable of providing informed consent (which is not to include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing associated with this investigation at an approved study site and at the intervals defined by this protocol

  • Patient who is age 18 years or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria:

  • Patient with an ongoing complication due to Cardiac Implantable Electronic Device (CIED) infection or CIED explant

  • Transvenous lead remnants within the heart from a previously implanted CIED (Note: transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)

  • Patient with a known LA thrombus

  • Patient with a ventricular arrhythmia due to a reversible cause

  • Patient indicated for implantation of a dual chamber pacemaker or cardiac resynchronization therapy (CRT)

  • Patient with another implanted medical device that could interfere with implant of the leadless pacemaker, such as an implanted inferior vena cava filter or mechanical tricuspid heart valve

  • Patient requires rate-responsive pacing therapy

  • Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)

  • Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable Angina) within 40 days

  • Inability to access femoral vein with a 21-French or larger inner diameter introducer sheath due to known anatomy condition, recent surgery, and/ or other relevant condition

  • Patient who has an active implanted electronic medical device intended for chronic use concomitantly with the study system, such as a left ventricular assist device (LVAD). Note that a temporary pacing wire is allowed.

  • Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)

  • Patient with a known cardiovascular anatomy that precludes implant in the right ventricle

  • Patient with a known allergy to any system components

  • Patient with a known or suspected intolerance to S-ICD conversion testing, based on physician discretion

  • Patient is not likely to have meaningful survival** for at least 12 months (documented or per investigator's discretion)

  • Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/ registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.

  • Patient who is a woman of childbearing potential who is known to be pregnant at the time of study enrollment (method of assessment upon investigator's discretion)

    [i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.

[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.

[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated System implant

[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse Generator; Patients with an existing S-ICD PG subject to the electrical overstress field action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219, or future BSC S-ICD Pulse Generator

*Significant cardiac scar is defined as a scar involving at least one ventricular myocardial segment (i.e., basal infero-septum) as identified in the official findings of a cMRI, or nuclear viability study, or echo report by the interpreting radiologist/ cardiologist who is not affiliated with the study

**meaningful survival means that a patient has a reasonable quality of life and functional status

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: MODULAR ATP Study Participants

All subjects that signed the informed consent were included.

Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware.

Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.

Altri nomi:
  • Comunicazione dell'S-ICD al pacemaker cardiaco leadless (LCP)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety Endpoint 1: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 6 Months
Lasso di tempo: Implant through 6 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-Free Rate Subjects will be assessed for safety issues related to the procedure or system through 6 months post implant

Implant through 6 Months Post-Implant
Safety Endpoint 2: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 12 Months
Lasso di tempo: Implant through 12 Months Post-Implant

Major EMPOWER MPS System- and Procedure-related Complication-free Rate

Subjects will be assessed for safety issues related to the procedure or system through 12 months post implant

Implant through 12 Months Post-Implant
Primary Effectiveness Endpoint 1: Percentage of Body Postures With Communication Success Between the S-ICD and EMPOWER PG
Lasso di tempo: At the 6 Month Follow-up

Communication Success between the S-ICD and EMPOWER PG

Data from subjects will be assessed for effectiveness of communication between S-ICD and the EMPOWER PG by evaluating if a paced beat is present during communication testing in four postures: upright, supine, and right and left side.

At the 6 Month Follow-up
Primary Effectiveness Endpoint 2: Percentage of Subjects Classified as a Pacing Capture Threshold (PCT) Responder
Lasso di tempo: At the 6 Month Follow-up

Proportion of Subjects with Adequate Pacing Capture Threshold

Effectiveness will be confirmed by evaluating the percentage of subjects considered to be a PCT Responder, defined as a subject with a PCT measurement of ≤ 2.0 V @ 0.4 ms pulse width

At the 6 Month Follow-up

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Secondary Effectiveness Endpoint: Subject-specific Slope of EMPOWER PG Sensor-Indicated Rate to the Subject's Workload on Treadmill Test
Lasso di tempo: At the 3 Month Visit

Metabolic-Chronotropic Relation Slope (MCR Slope) from the Kay-Wilkoff Model

Using the Kay-Wilkoff model, data will be assessed to evaluate the proportionality of the EMPOWER PG's sensor-indicated rate to the subject's workload during the treadmill test

At the 3 Month Visit
Secondary Safety Endpoint
Lasso di tempo: Implant through 2 years post-implant

All-Cause Survival; data not reported as it is still being collected

Implant through 2 years post-implant

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Reinoud Knops, MD, PhD, Amsterdam University Medical Centre
  • Investigatore principale: Lluis Mont, MD, PhD, Hospital Clinic, University of Barcelona
  • Investigatore principale: Vivek Reddy, MD, The Mount Sinai Hospital
  • Investigatore principale: Michael Lloyd, MD, Emory University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 luglio 2021

Completamento primario (Effettivo)

6 maggio 2024

Completamento dello studio (Stimato)

31 dicembre 2030

Date di iscrizione allo studio

Primo inviato

8 marzo 2021

Primo inviato che soddisfa i criteri di controllo qualità

12 marzo 2021

Primo Inserito (Effettivo)

15 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

There is no plan to share IPD with other researchers in this study.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi